Provided by Tiger Trade Technology Pte. Ltd.

Accendra Health Inc

0.5627
-0.0493-8.06%
Post-market: 0.56400.0013+0.23%19:30 EDT
Volume:2.00M
Turnover:1.15M
Market Cap:43.27M
PE:-0.14
High:0.6346
Open:0.6200
Low:0.5544
Close:0.6120
52wk High:5.60
52wk Low:0.5544
Shares:76.90M
Float Shares:56.51M
Volume Ratio:1.25
T/O Rate:3.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9457
EPS(LYR):-14.3179
ROE:-198.35%
ROA:0.64%
PB:-0.08
PE(LYR):-0.04

Loading ...

Accendra Health Sets Oct. 5 Start Date for Incoming CEO Kenneth Gardner-Smith

Reuters
·
Sep 29

Analysts Conflicted on These Healthcare Names: Petmed Express (PETS) and Accendra Health (ACH)

TIPRANKS
·
Sep 21

Accendra Health Names Kenneth Gardner-Smith as Next CEO, Effective Q4 2026

Reuters
·
Sep 17

Accendra Health, - Kenneth Gardner-Smith Expected to Assume CEO Role Early in Q4 2026

THOMSON REUTERS
·
Sep 17

Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company’s Next Chapter of Growth

THOMSON REUTERS
·
Sep 17

Accendra Health, - Edward Pesicka to Retire from Board When Gardner-Smith Assumes CEO Role

THOMSON REUTERS
·
Sep 17

Avon Technologies: Buy Rating Reiterated on New US$20.3m ACH GEN II Order and Unchanged $2390 Price Target

TIPRANKS
·
Sep 02

Press Release: HashKey Announces 2026 Interim Results

Dow Jones
·
Aug 27

Accendra Health updates capital allocation, CEO succession plans

TIPRANKS
·
Aug 17

Accendra Health Sells First of Two Non-Core Assets, Expects About $45 Million Cash Injection

Reuters
·
Aug 17

Accendra Health - Sale of Two Non-Core Assets to Provide $45 Mln Cash Injection in Q3 and Q4

THOMSON REUTERS
·
Aug 17

Accendra Health - Will not Implement At-the-Market Issuance Program

THOMSON REUTERS
·
Aug 17

Accendra Health - Board Expects to Announce CEO Successor by Mid-September 2026

THOMSON REUTERS
·
Aug 17

Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans

THOMSON REUTERS
·
Aug 17

Accendra Health Inc : UBS Cuts Target Price to $1.5 from $4.5

THOMSON REUTERS
·
Aug 14

Accendra Health is Maintained at Neutral by UBS

Dow Jones
·
Aug 14

UBS Adjusts Price Target on Accendra Health to $1.50 From $4.50, Keeps Neutral Rating

MT Newswires Live
·
Aug 13

U.S. Research Roundup-Airbnb, Five Below, Silgan Holdings

Reuters
·
Aug 13

Press Release: Chemtrade Logistics Income Fund Announces Results for the Second Quarter of 2026 and Reiterates 2026 Adjusted Ebitda Guidance of $485 to $525 Million

Dow Jones
·
Aug 13

Accendra Health Cut to Neutral from Buy by Citigroup

Dow Jones
·
Aug 11